Trial Title:
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
NCT ID:
NCT06622057
Condition:
Biliary Tract Cancer (BTC)
Conditions: Official terms:
Biliary Tract Neoplasms
Capecitabine
Conditions: Keywords:
BTC
cholangiocarcinoma
Biliary Tract Cancer
third-line
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Intervention:
Intervention type:
Drug
Intervention name:
D07001-Softgel Capsules
Description:
D07001-softgel capsule is an oral gemcitabine.
Arm group label:
D07001-Softgel Capsules 100 mg + Capecitabine
Arm group label:
D07001-Softgel Capsules 60 mg + Capecitabine
Intervention type:
Drug
Intervention name:
Placebo
Description:
Placebo has the same excipient with D07001-softgel but without active pharmaceutical
ingredients (APIs)
Arm group label:
Placebo + Capecitabine
Intervention type:
Combination Product
Intervention name:
Capecitabine
Description:
Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and
selective cytotoxic agent.
Arm group label:
D07001-Softgel Capsules 100 mg + Capecitabine
Arm group label:
D07001-Softgel Capsules 60 mg + Capecitabine
Arm group label:
Placebo + Capecitabine
Summary:
The object of this trial is to evaluate the efficacy of D07001-softgel capsules +
capecitabine compared with placebo + capecitabine by overall survival (OS).
Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to
receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with
capecitabine. Treatment will be continued until disease progression, death, withdraw
consent, or completing 12 treatment cycles , whichever occurs first.
Detailed description:
This is a Phase III, randomized, double-blind, multicenter, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of D07001-softgel capsules +
capecitabine tablets in participants with advanced BTC after failure on an intravenous
gemcitabine and cisplatin-based, and also failed on or refused FOLFOX or failed on
irinotecan and fluorouracil regimen. Approximately 195 participants (approximately 65 per
treatment arm) will be randomized 1:1:1 to one of the following treatment arms:
- Oral D07001 softgel capsules, 100 mg/day + capecitabine tablets (1000 mg/m2 twice
daily [bid])
- Oral D07001 softgel capsules, 60 mg/day + capecitabine tablets (1000 mg/m2 bid)
- Oral placebo softgel capsules + capecitabine tablets (1000 mg/m2 bid) A formal
interim futility analysis will be conducted when approximately 80 participants have
either experienced disease progression or death. Study participants will continue
study treatment until unacceptable toxicity, disease progression, death, withdrawal
of consent to treatment, or completing 12 treatment cycles, whichever comes first.
The EOT Visit will occur following unacceptable toxicity, disease progression,
completing 12 treatment cycles or withdrawal of consent to treatment. Follow-up
Period/Visits over phone call will be conducted for participants on 30 ± 3 days,
every month; and at 365 ± 3 days following the EOT Visit.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Provide written informed consent prior to any study procedures and agree to adhere
to all protocol requirements
2. Aged at least 18 years.
3. Has histopathological or cytologic diagnosis of unresectable, locally advanced or
metastatic BTC.
4. Has measurable disease as assessed by RECIST v1.1.
5. Must have failed on a gemcitabine + cisplatin-based chemotherapy, regardless of
whether immune checkpoint inhibitor, such as durvalumab or pembrolizumab, or S-1
(tegafur, gimeracil, and oteracil potassium), was also administered. Oxaliplatin or
carboplatin may be substituted for cisplatin when renal or auditory function is of
concern. Participants also have failed (disease progression or intolerance) on, or
refused FOLFOX chemotherapy, including modified FOLFOX variants, or failed on or
irinotecan + fluorouracil chemotherapy.
6. Participants with tumors expressing the following biomarkers can be enrolled if they
have not previously received FOLFOX but have received appropriate targeted therapies
until disease progression or intolerance: fibroblast growth factor receptors
aberrations, microsatellite instability biomarker/deficient DNA mismatch repair, or
isocitrate dehydrogenase mutations.
7. ECOG PS of 0-2.
8. Life expectancy is ≥12 weeks.
9. Has adequate bone marrow function, demonstrated by: (a) ANC ≥1500 cell/mm3; (b)
Platelet count ≥85,000 cells/mm3; (c) Hemoglobin ≥9 g/dL.
10. Has adequate liver function, demonstrated by: (a) AST and ALT ≤2.5 × ULN, or ≤5.0 ×
ULN in the case of liver lesions; (b) Total bilirubin ≤1.5 × ULN; (c) Albumin ≥3.0
g/dL; (d) INR <1.5.
11. Has adequate renal function, demonstrated by CCR ≥ 45 mL/min or eGFR ≥ 45
mL/min/1.73 m2
12. No clinically significant abnormalities in coagulation results.
13. Participant is eligible to participate if not pregnant (as demonstrated by serum
pregnancy testing at screening), not breastfeeding, and at least 1 of the following
conditions applies:
1. Not of childbearing potential (CBP).
2. A participant of CBP who is sexually active with a partner who could impregnate
them agrees to use a highly effective form of contraception during the study
and for at least 30 days after the end of study intervention.
14. With partners of childbearing potential whom they could impregnate must agree to use
contraception during the study and for 90 days after the end of study intervention.
15. Participants who are able to donate sperm must refrain from sperm donation during
the study and for 90 days after the end of study intervention.
16. Participant is willing to comply with the protocol-required visit schedule and visit
requirements.
17. More than 14 days have elapsed between the participant completing a prior line of
chemotherapy or target therapy, and enrollment. More than 28 days have elapsed
between the participant receiving concurrent radiotherapy (CCRT) and enrollment.
Exclusion Criteria:
1. Has a diagnosis of active malignancy other than BTC within the past 2 years, except
nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with
curative intent.
2. Participant discontinued prior gemcitabine due to pulmonary or hepatic toxicity or
hemolytic uremic syndrome, hypersensitivity, allergic reaction, or intolerance.
3. Participant had a prior unanticipated severe reaction to capecitabine or metabolites
or to fluoropyrimidine therapy.
4. Participant received treatment with brivudine, sorivudine, or its chemically related
analogs ≤28 days prior to the date of enrollment.
5. Participant is currently receiving flucytosine treatment.
6. Participant has residual toxicity from prior chemotherapy or CCRT that is Grade ≥2
(residual Grade 2 neuropathy and alopecia are permitted).
7. Participant has any gastrointestinal disorder or prior gastrointestinal surgery that
would significantly impede absorption of an oral agent, such as gastrectomy, Crohn's
disease, ulcerative colitis, or short gut syndrome.
8. Participant has known brain or leptomeningeal metastases.
9. Participant had major surgery or definitive ablation-intent (excluding palliative
radiotherapy for bone metastasis) radiation therapy within the past 28 days.
10. Participant has any active disease or condition that would not permit compliance
with the protocol.
11. Participant has clinically significant cardiovascular disease (e.g., uncontrolled
hypertension, unstable angina, congestive heart failure, New York Heart Association
Grade 2 or greater), or uncontrolled serious cardiac arrhythmia.
12. Participant has documented cerebrovascular disease.
13. Participant has a seizure disorder not controlled with medication (based on
Investigator's decision).
14. Participant has received an investigational agent within 28 days of enrollment.
15. Participant has an uncontrolled active viral, bacterial, or systemic fungal
infection.
16. Participant has positive hepatitis B surface antigen with positive hepatitis B virus
DNA ≥2000 copies/mL and/or anti-hepatitis C virus antibody.
17. Participant has received yellow fever vaccine or other live attenuated vaccine(s)
within the 4 weeks before screening.
18. Participant has a history of drug or alcohol abuse within the year before signing
the informed consent form.
19. Participant has any other serious medical condition that, in the Investigator's
medical opinion, would preclude safe participation in or compliance with the
clinical trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Address:
City:
Kaohsiung
Zip:
807
Country:
Taiwan
Contact:
Last name:
Li-Tzong Chen, M.D.
Phone:
886-73121101
Investigator:
Last name:
Li-Tzong Chen
Email:
Principal Investigator
Start date:
April 1, 2025
Completion date:
December 31, 2027
Lead sponsor:
Agency:
InnoPharmax Inc.
Agency class:
Industry
Source:
InnoPharmax Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06622057
